The US Food and Drug Administration (FDA) has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for ...

In June 2025, AstraZeneca announced a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab ...

Biomarker-targeted adjuvant therapy improved survival in early-stage NSCLC, highlighting the importance of testing and reducing treatment disparities.

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for chemotherapy in certain patients with NSCLC.

Pembrolizumab combined with chemoradiation shows promising long-term efficacy and safety in treating advanced non-small cell ...

When small-cell lung cancer (SCLC) has spread to distant parts of the body, it’s classified as extensive-stage, which applies ...

(Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced positive pivotal data for ...

Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and stage of SCLC.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...